Weight management · Phase 2
ZUPREME 2: petrelintide with diabetes
What was tested?
Petrelintide versus placebo in adults with overweight or obesity and type 2 diabetes. ↗
Registered primary question: Percentage change in body weight at week 28. ↗
What is available so far
This card describes a registered study. No publication results have been appraised for this card. The retrieved registry record does not contain posted results. ↗
Keep in context: This registered population has type 2 diabetes. The retrieved record contains no posted results; this card does not substitute for a published results appraisal. ↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 221 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Double
- Design
- Parallel
- Eligible ages
- 18 Years; maximum not specified
- Registry results
- Not posted in this snapshot
Registry source ↗ · Updated 2026-09-09; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) ↗
Protocol identifier: ZP8396-24115. Sponsor: Zealand Pharma.
Retrieved 2026-09-20; SHA-256 12627b63a37b7c06a1d1772d78953ac7aef94b809c2be4b848f05d407fa796a3.